Search clinical trials for: BAY1841788 (ODM-201)

Total 4612 results

Bayer

Recruiting

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

Cancer

Korea, Republic of, Spain, United States, China, Australia, Austria, Belgium, Brazil, Colombia, Czechia, Estonia, Finland, France, Germany, Hungary, Israel, Italy, Japan, Latvia, Lithuania, Netherlands, Peru, Poland, Portugal, Romania, Russian... and more
Sir Mortimer B. Davis - Jewish General Hospital

Recruiting

Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)

Castration-resistant Prostate Cancer | Metastatic Prostate Cancer

Canada
Bayer
Orion Corporation, Orion Pharma

Completed

Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer (ARAMIS)

Prostate Cancer Non-Metastatic | Castration-Resistant

Belgium, France, Poland, Spain, Canada, United States, Estonia, Portugal, Taiwan, Japan, Russian Federation, Finland, Germany, Austria, Czechia, Hungary, Australia, Brazil, South Africa, Latvia, Italy, United Kingdom, Turkey, Serbia, Ro... and more
Bayer

Completed

Imaging Study to Compare Effects of Darolutamide and Enzalutamide With Respect to Placebo on the Blood Flow in the Brain in Healthy Male Volunteers.

Cerebrovascular Circulation

United Kingdom
Orion Corporation, Orion Pharma
Endo Pharmaceuticals

Completed

Bioavailability Study of ODM-201 in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer (ARAFOR)

Prostate Cancer

Latvia
Orion Corporation, Orion Pharma

Completed

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Prostate Cancer

United States, United Kingdom, Finland, France, Estonia, Czech Republic
Orion Corporation, Orion Pharma
Endo Pharmaceuticals

Completed

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Prostate Cancer

United States, United Kingdom, Finland, France, Czech Republic, Estonia
Orion Corporation, Orion Pharma
Bayer

Completed

Mass Balance, Pharmacokinetics, Biotransformation and Bioavailability Study of ODM-201 in Healthy Male Subjects (ARIADME)

Healthy

United Kingdom
Gustave Roussy, Cancer Campus, Grand Paris

Unknown

A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer (ODENZA)

Metastatic Castrate-resistant Prostate (CRPC) Cancer

France
MedImmune LLC
AstraZeneca

Completed

Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age (FluMist)

Healthy | Influenza

United States
Bayer

Completed

Phase 1 Dose Escalation Study of BAY 1841788 in Japanese Metastatic Castration-resistant Prostate Cancer (mCRPC) Subjects

Prostatic Neoplasms

Japan
Orion Corporation, Orion Pharma
Quotient Clinical

Completed

Impact of Changing the Dosing Regimen on the PK Profile of ODM-203 (KIPEV)

Healthy

United Kingdom
Orion Corporation, Orion Pharma

Completed

ODM-207 in Patients With Advance Solid Tumours (BETIDES)

Solid Tumors

Finland
Orion Corporation, Orion Pharma

Completed

Safety and Tolerability of ODM-203 in Subjects With Advanced Solid Tumours (KIDES-203)

Solid Tumours

France, Finland, Spain, Italy, Denmark, United Kingdom
University Health Network, Toronto
Bayer; Prostate Cancer Canada

Not yet recruiting

Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer (SChLAP/IDC)

Prostate Cancer

Canada
Bayer

Completed

Drug-drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1, and OATP1B3 (Uptake Transporters) Probe Substrate

Healthy Volunteers | Pharmacokinetics | Drug Interaction

Germany
Translational Research in Oncology
Bayer

Completed

A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide

Breast Cancer Female

Germany, Canada, United States
Orion Corporation, Orion Pharma

Completed

Safety and Pharmacokinetics of ODM-209 (STESIDES)

Advanced Breast Cancer | Metastatic Breast Cancer | Castration-resistant Prostate Cancer | Prostate Cancer Metastatic

Finland, France, Denmark
Swiss Group for Clinical Cancer Research

Terminated

ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.

Prostate Cancer | Prostate Cancer Metastatic

France, Switzerland, Spain, Italy
European Organisation for Research and Treatment...
Bayer

Active, not recruiting

ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer

Prostate Cancer

Belgium, Spain, France, Italy
Bayer
Orion Corporation, Orion Pharma

Completed

Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (ARASENS)

Metastatic Hormone-sensitive Prostate Cancer

Belgium, France, Sweden, China, Canada, United States, Spain, Taiwan, Japan, Finland, Korea, Republic of, Australia, Brazil, Czechia, Israel, Italy, Netherlands, Russian Federation, Bulgaria, United Kingdom, Germany, Poland, Mexico
Bayer
Orion Corporation, Orion Pharma

Completed

Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201)

Hepatic Insufficiency | Renal Insufficiency | Pharmacokinetics

Germany
NewG Lab Pharma

Active, not recruiting

KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma | Fibrolamellar Carcinoma

Korea, Republic of
Chang Gung Memorial Hospital

Completed

Nonoperative Management Protocol in Patients With Blunt Splenic Injuries

Blunt Injuries
Duke University
Centers for Disease Control and Prevention; Children's Hospital Medical Center...

Completed

Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women (Tdap/IIV)

Pregnancy

United States
TScan Therapeutics, Inc.

Recruiting

A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

Melanoma | Cervical Cancer | Head and Neck Cancer | HPV-Related Malignancy | Ovarian Cancer | HPV-Related Carcinoma | HPV-Related Cervical Carcinoma | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Non-small Cell Carcinoma | HPV - Anogenital Human Papilloma Virus Infection | HPV-Related Adenocarcinoma | HPV-Related Adenosquamous Carcinoma and other conditions

United States
Unity Health Toronto
Stryker Orthopaedics

Unknown

Assessing the Wear Rates of the ADM/MDM Hips Using 3D X-ray Analysis

Arthroplasty, Replacement, Hip

Canada
Bayer

Active, not recruiting

A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described (DAROL)

Prostate Cancer

United States, Canada, Japan, Spain, Germany, Belgium, Argentina, Austria, Brazil, Greece, Italy, Russian Federation, Taiwan, China, Denmark, France, Colombia
Maria Sklodowska-Curie National Research Institute...

Recruiting

Phase 1b/2 Study of Liposomal Annamycin (L-Annamycin) in Subjects With Previously Treated Soft-Tissue Sarcomas (STS) With Pulmonary Metastases (ANNA-SARC)

Soft Tissue Sarcoma | Pulmonary Metastasis

Poland
Mamta Parikh
National Cancer Institute (NCI)

Recruiting

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

Stage IV Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Advanced Prostate Adenocarcinoma

United States
Bayer

Terminated

Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC) (DaroAcT)

Prostatic Cancer, Castration-Resistant

United States
Bayer

Completed

An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World Settings (DEAR)

Non-metastatic Castration-resistant Prostate Cancer

United States
Desentum Oy

Completed

Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy

Birch Pollen Allergy

Finland
Orion Corporation, Orion Pharma

Completed

Safety and Tolerability Study With Single Ascending Doses of ODM-102

Healthy Volunteers

Finland
Hookipa Biotech GmbH

Recruiting

A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

HPV-Related Squamous Cell Carcinoma

United States, Spain, Netherlands
Addpharma Inc.

Completed

A Study to Evaluate the Efficacy and Safety of AD-208

Androgenetic Alopecia

Korea, Republic of
Addpharma Inc.

Not yet recruiting

Phase III Study to Evaluate the Efficacy and Safety of AD-209

Hypertension,Essential

Korea, Republic of
Bayer

Not yet recruiting

An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea

Non-metastatic Castration-resistant Prostate Cancer | Metastatic Hormone-sensitive Prostate Cancer

Korea, Republic of
Bayer

Recruiting

A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

Non-metastatic Castration-resistant Prostate Cancer

India
Universidade Federal de Pernambuco

Unknown

Immediate Effect of Whole Body Vibration on Diabetics and Non-diabetics (DM)

Diabetes Mellitus, Type 2

Brazil
Orion Corporation, Orion Pharma

Completed

Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations (PARPOC)

Parkinson's Disease
Assistance Publique - Hôpitaux de Paris

Recruiting

Follow-up in Pediatric Intensive Care Unit (APRELAREA)

Intensive Care Psychosis

France
Bayer

Active, not recruiting

A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study. (ARASEC)

Metastatic Hormone-sensitive Prostate Cancer

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.

Influenza

United States
Bayer

Recruiting

A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide (ARAMON)

Biochemically Recurrent Prostate Cancer

United States
Bayer

Active, not recruiting

A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely

Prostate Cancer

United States
Oxford Vacmedix UK Ltd.

Recruiting

First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine

Ovarian Cancer | Prostate Cancer | Non Small Cell Lung Cancer

United Kingdom
Canopy Growth Corporation

Completed

Study to Assess the Safety, Tolerability, and Effects of CHI-202 to Support Recovery From Physical Activity

Delayed Onset Muscle Soreness (DOMS)

United States
Orion Corporation, Orion Pharma

Completed

Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of ODM-106 in Healthy Volunteers (FIMPAM)

Healthy Volunteer Study

Germany
University of Calgary

Not yet recruiting

Cannabis for the Prophylactic Treatment of Migraine

Chronic Migraine

Search clinical trials for: BAY1841788 (ODM-201)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations